Return to Results

Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma

new search

Trial Conditions
  • Esophageal Cancer
  • Gastric Cancer
What is the purpose of this trial?

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy after surgery may kill any remaining tumor cells following surgery. It is not yet known which chemotherapy and radiation therapy regimen is more effective in treating stomach or esophageal cancer. PURPOSE: Randomized phase III trial to compare two different chemotherapy and radiation therapy regimens in treating patients who have undergone surgery for stomach or esophageal cancer.

Date & Status

Active, not recruiting

Who can Participate?


18 and older



1. Required Tumor Parameters

1.1 Patients must have histologically diagnosed adenocarcinoma of the stomach or
gastroesophageal junction. Adenocarcinomas of the esophagus that are not involving
the gastroesophageal junction are not eligible.

1.2 Patients must have had en bloc resection of all known tumor. The surgical
resection must have been done with a curative intent.

1.3 Patients must have tumor extension beyond muscularis propria and/or nodal
involvement without evidence of M1 disease.

- Patients can have stages IB if there is evidence of either node-positive (N1)
disease or tumor extension beyond the muscularis propria (i.e., T1, N1, M0
patients are eligible but patients with T2, N0, M0 are allowed only if there is
extension beyond the muscularis propria).

- Patients can have stages II, IIIA, IIIB or stage IV with M0 (i.e., T4N2M0).

- Stages 0, IA, or any stage with M1 are not allowed. (see Appendix I for TNM
staging guide).

1.4 Patients with known unresected cancer, recurrent cancer, microscopic evidence of
tumor at the distal or proximal line of stomach resection, noncontiguous resection of
tumor, or M1 (metastatic) disease are ineligible.

2. Prior Therapy

2.1 No prior therapy (except hormonal or biologic) for other malignancies is allowed
except for adequately treated basal cell or squamous cell skin cancer, noninvasive
carcinoma in situ which has been fully resected, or other cancer for which the
patient has been disease free for five years.

2.2 Patients who have had any previous chemotherapy or radiotherapy are ineligible.

3. Patient Characteristics

3.1 Patients must have an ECOG (CTC) performance status of 0, 1 or 2.

3.2 Patients are required to have an adequate total caloric intake to allow them to
maintain their post-surgical body weight. Patients must have documentation of stable
weight (or less than 2 pounds weight loss) for at least one week prior to

3.3 All patients must be evaluated by a radiation oncologist (prior to enrollment) to
ensure that the patient is an appropriate candidate for radiation therapy.

3.4 Patients may not have unilateral renal function (only one functioning kidney) as
determined by CT scan with contrast, urogram, renal scan, or other study.

3.5 Pregnant or lactating women may not participate. Men and women of reproductive
potential may not participate unless they have agreed to use an effective
contraceptive method or practice abstinence while in this study.

- The effects of therapeutic radiotherapy are known to be teratogenic.

- The effects of Epirubicin, Cisplatin, and 5-FU on a developing human fetus at
the recommended therapeutic dose are less well known.

- For this reason and because DNA alkylating agents are known to be teratogenic,
women of childbearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control) prior to study entry and for the
duration of study participation.

- Should a woman become pregnant or suspect she is pregnant while participating on
this study, she should inform her treating physician immediately. Because the
risk of toxicity in nursing infants secondary to Epirubicin, Cisplatin, and 5-FU
treatment of the mother is unknown but may be harmful, breastfeeding should be

3.6 Patients with any of the following cardiac conditions are ineligible:

- Uncontrolled high blood pressure

- Unstable angina

- Symptomatic congestive heart failure

- Myocardial infarction < 6 months prior to registration

- Serious uncontrolled cardiac arrhythmia

- New York Heart Association classification III or IV.

3.7 No uncontrolled serious medical or psychiatric illness which would prevent
compliance with treatment or adequate informed consent.

3.8 Patients with active infectious process are ineligible.

3.9 Patients with grade 2 or greater peripheral neuropathy at baseline are

4. Required Initial Laboratory Values:

- Granulocytes ≥ 1,500/μl

- Platelet count ≥ 100,000/μl

- Creatinine ≤ 1.5 mg/dl

- Bilirubin ≤ 2.0 mg/dl

- AST ≤ 3x upper limits of normal

Gender: Both
Steward Physician(s)
  • Charles S. Fuchs, MD
  • Steven R. Alberts, MD
  • Daniel G. Haller, MD
  • St. Elizabeth's Medical Center - Active, not recruiting
  • Saint Anne's Hospital - Active, not recruiting
  • Morton Hospital - Active, not recruiting
Trial Interventions
  • cisplatin
  • epirubicin hydrochloride
  • fluorouracil
  • leucovorin calcium
  • radiation therapy
Physician Researcher

Investigator Name:

  • Charles S. Fuchs, MD
  • Steven R. Alberts, MD
  • Daniel G. Haller, MD

Other Information

Sponsor: Alliance for Clinical Trials in Oncology
Phase: Phase 3
Trial ID: NCT00052910
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2015 Steward Health Care
Connect Healthcare Panacea CMS Solutions